Community seroprevalence and risk factors for SARS-CoV-2 infection in different subpopulations in Vellore, India, and their implications for future prevention.
COVID
India
SARS-CoV-2
Seroprevalence
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
10
11
2021
revised:
22
12
2021
accepted:
22
12
2021
pubmed:
1
1
2022
medline:
3
3
2022
entrez:
31
12
2021
Statut:
ppublish
Résumé
The aim of this study was to inform public health policy decisions through the assessment of IgG antibody seroprevalence in the population and the risk factors for SARS-CoV-2 infection. The seroprevalence of IgG antibodies among different subpopulations at the end of the first and second waves of the pandemic was estimated. Various risk factors associated with seropositivity, including sociodemography, IgG antibodies against endemic human coronavirus, and vaccination status, were also assessed. For all 2433 consenting participants, the overall estimated seroprevalences at the end of first and second waves were 28.5% (95% CI 22.3-33.7%) and 71.5% (95% CI 62.8-80.5%), respectively. The accrual of IgG positivity was heterogeneous, with the highest seroprevalences found in urban slum populations (75.1%). Vaccine uptake varied among the subpopulations, with low rates (< 10%) among rural and urban slum residents. The majority of seropositive individuals (75%) were asymptomatic. Residence in urban slums (OR 2.02, 95% CI 1.57-2.6; p < 0.001), middle socioeconomic status (OR 1.77, 95% CI 1.17-2.67; p = 0.007), presence of diabetes (OR 1.721, 95% CI 1.148-2.581; p = 0.009), and hypertension (OR 1.75, 95% CI 1.16-2.64; p = 0.008) were associated with seropositivity in multivariable analyses. Although considerable population immunity has been reached, with more than two-thirds seropositive, improved vaccination strategies among unreached subpopulations and high-risk individuals are suggested for better preparedness in future.
Identifiants
pubmed: 34971822
pii: S1201-9712(21)01255-8
doi: 10.1016/j.ijid.2021.12.356
pmc: PMC8712712
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-146Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflicts of interest to declare.
Références
Lancet Infect Dis. 2021 Feb;21(2):203-212
pubmed: 33091374
JAMA Netw Open. 2021 Sep 1;4(9):e2124116
pubmed: 34524438
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
PLoS One. 2021 Jul 29;16(7):e0255412
pubmed: 34324603
PLoS One. 2016 Aug 04;11(8):e0160706
pubmed: 27490200
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Int J Infect Dis. 2021 Jul;108:145-155
pubmed: 34022338
J Infect Dis. 2005 Jun 15;191(12):2033-7
pubmed: 15897988
Clin Infect Dis. 2022 Apr 9;74(7):1208-1219
pubmed: 34216472
J Med Virol. 1979;3(4):313-20
pubmed: 113504
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
Viruses. 2021 Jun 10;13(6):
pubmed: 34200766
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939
Epidemiol Infect. 2021 Feb 04;149:e39
pubmed: 33536108
Viruses. 2021 Sep 07;13(9):
pubmed: 34578363
One Health. 2021 Dec;13:100283
pubmed: 34222606
Sci Rep. 2021 May 18;11(1):10551
pubmed: 34006960
BMJ. 2021 Jul 21;374:n1856
pubmed: 34290075
Lancet Reg Health Eur. 2021 May 21;5:100119
pubmed: 34557824
Pathogens. 2021 Sep 21;10(9):
pubmed: 34578254
Lancet Glob Health. 2021 Feb;9(2):e110-e111
pubmed: 33197394
Nature. 2021 Oct;598(7880):338-341
pubmed: 34438440
Int J Hyg Environ Health. 2021 Aug;237:113836
pubmed: 34481208
Emerg Infect Dis. 2021 Dec;27(12):3124-3127
pubmed: 34533453
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):136-139
pubmed: 32317412
BMC Res Notes. 2021 Jul 8;14(1):262
pubmed: 34238344
Pathog Dis. 2020 Apr 1;78(3):
pubmed: 32510562
Lancet Public Health. 2021 Apr;6(4):e202-e209
pubmed: 33556328
Emerg Infect Dis. 2020 Oct;26(10):2416-2419
pubmed: 32614768
BMJ Open. 2021 Sep 23;11(9):e053791
pubmed: 34556519
J Med Virol. 1984;13(2):131-48
pubmed: 6319588
Viruses. 2021 Sep 10;13(9):
pubmed: 34578387
J Med Virol. 2021 Dec;93(12):6696-6702
pubmed: 34331713
Int J Infect Dis. 2020 May;94:44-48
pubmed: 32171952
Lancet Infect Dis. 2021 Dec;21(12):1665-1676
pubmed: 34399090
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Virol Methods. 2013 Feb;187(2):413-20
pubmed: 23174159
PLoS One. 2021 Nov 30;16(11):e0260164
pubmed: 34847149